- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07106255
- Original Trial
Task-oriented Training Intervention for Multiple Sclerosis Patients.
Task-oriented Training Intervention for Multiple Sclerosis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18071
- Faculty of Health Sciences. University of Granada
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Multiple Sclerosis by a neurologist.
- Aged over 18 years old.
- Acceptance and signature of the informed consent.
Exclusion Criteria:
- A cognitive level or condition that did not allow completion of the evaluations.
- An exacerbation of MS during the previous 3 months.
- Presence of interfering musculoskeletal, neurological, orthopaedic, and/or rheumatic disorders affecting hand and/or finger mobility, including previous trauma or fracture of the upper extremity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Task-oriented training program
|
Participants included in the experimental group will underwent an 8-week TOT intervention, administered twice weekly, with each session lasting 45 minutes. Within this framework, the intervention will comprise sessions involving meaningful and repetitive activities tailored to both the patient and their specific context. The occupations will be selected by each participant through the Canadian Occupational Performance Measure (COMP) tool in the initial assessment. The activities were randomly ordered and focused on the reconstruction of complete tasks. To support task segmentation, a range of custom-designed materials will be employed, alongside therapeutic tools and materials such as therapeutic putty, TheraBand, and others commonly used in physical rehabilitation interventions. Throughout the intervention, participants will receive positive reinforcement that will fade over the time to prevent unnecessary dependency. |
|
Active Comparator: Standard medical care and leaflet fatigue management
|
Participants included in the control group will continue with their usual treatment and will receive a pamphlet containing information on fatigue management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occupational Performance
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
The main variable in this study will be the Canadian Occupational Performance Measure (COPM).
This tool measures the perception of problems related to the overall quality of performance, development and satisfaction with particular occupations.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
The level of fatigue will be assessed with the Modified Impact Fatigue Scale (MFIS) and the Fatigue Severity Scale (FSS).
The MFIS consists of items from which a total score is obtained and for each subscale.
Scores range from 0 to 36 with higher scores indicating a greater impact of fatigue on activities.
The FSS consists of 9 items that are rated on a scale of 1 to 7. A higher score indicates a higher agreement with the statement presented in each item.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Upper limb strengh
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Upper limb strength will be assessed using the Arm Curl Test (ACT).
The ACT consists of performing as many arm curls as possible in 30 seconds while seated in a chair.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Upper limb strengh 2
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Upper limb strength will be assessed using a hand and pinch dynamometer.
The dynamometer and hand dynamometer measure grip and pinch strength respectively.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Motor speed
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Motor speed will be assessed with the Finger Tapping Test (FTT).
In this test, the number of finger taps the participant is able to perform in three attempts of 20 seconds each is counted.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Manual dexterity - 9HPT
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Manual dexterity will be assessed using the Nine Hole Peg Test (9HPT).
9HPT requires the participant to place and then remove nine pegs, one at a time, into nine holes on a board as quickly as possible.
The test is performed separately with each hand, and the time taken to complete the task is recorded.
Shorter completion times indicate better manual dexterity.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Manual dexterity - Purdue
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Manual dexterity will be assessed using the Purdue Pegboard Test. Purdue Pegboard Test involves placing as many pins as possible into holes on a board. It includes subtests for dominant and non-dominant hand, both hands simultaneously, and an assembly task. Higher scores reflect better dexterity. |
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Manual dexterity - CRT
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Manual dexterity will be assessed using the Coin Rotation Test (CRT). CRT assesses the coordination and speed of the fingers by rotating a coin clockwise with three fingers of the hand (thumb, index and middle finger) as fast as possible. |
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
|
Satisfaction and adherence with the intervention
Time Frame: Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Satisfaction and adherence with the intervention will be recorded with the Sport Injury Rehabilitation Adherence Scale (SIRAS).
Although originally designed for sport settings, it has been used to assess adherence and satisfaction in chronic populations.
|
Baseline and at 8 weeks at the end of the intervention, and through study completion, at 1, 3, 6, and 12 months post-intervention (an average of 1 year)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 036-N-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Task-oriented training
-
Foundation University IslamabadEnrolling by invitation
-
Universitas PadjadjaranNot yet recruitingStroke, CerebrovascularIndonesia
-
Riphah International UniversityCompletedStroke, CardiovascularPakistan
-
Riphah International UniversityCompleted
-
Riphah International UniversityCompletedStroke (CVA) or TIAPakistan
-
University of LahoreCompletedStroke | Chronic Stroke PatientPakistan
-
Ankara Medipol UniversityBalikesir Ataturk City HospitalCompleted
-
Riphah International UniversityRecruitingParkinson DiseasePakistan
-
Washington University School of MedicineCompleted
-
Horus UniversityCompleted